EMBL-EBI | Chemical Biology | ChEBI
Example searches: iron*, InChI=1S/CH4O/c1-2/h2H,1H3, caffeine | Advanced Search
| Formula | C22H30O5 |
| Net Charge | 0 |
| Average Mass | 374.477 |
| Monoisotopic Mass | 374.20932 |
| SMILES | [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@@]21C |
| InChI | InChI=1S/C22H30O5/c1-12-8-14-15-5-7-22(27,18(26)11-23)21(15,3)10-17(25)19(14)20(2)6-4-13(24)9-16(12)20/h4,6,9,12,14-15,17,19,23,25,27H,5,7-8,10-11H2,1-3H3/t12-,14-,15-,17-,19+,20-,21-,22-/m0/s1 |
| InChIKey | VHRSUDSXCMQTMA-PJHHCJLFSA-N |
| Wikipedia |
|---|
| Roles Classification |
|---|
| Chemical Role: | environmental contaminant Any minor or unwanted substance introduced into the environment that can have undesired effects. |
| Biological Roles: | immunosuppressive agent An agent that suppresses immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-cells or by inhibiting the activation of helper cells. In addition, an immunosuppressive agent is a role played by a compound which is exhibited by a capability to diminish the extent and/or voracity of an immune response. analgesic An agent capable of relieving pain without the loss of consciousness or without producing anaesthesia. In addition, analgesic is a role played by a compound which is exhibited by a capability to cause a reduction of pain symptoms. xenobiotic A xenobiotic (Greek, xenos "foreign"; bios "life") is a compound that is foreign to a living organism. Principal xenobiotics include: drugs, carcinogens and various compounds that have been introduced into the environment by artificial means. antiviral agent A substance that destroys or inhibits replication of viruses. antifungal agent An antimicrobial agent that destroys fungi by suppressing their ability to grow or reproduce. adrenergic agent Any agent that acts on an adrenergic receptor or affects the life cycle of an adrenergic transmitter. antimicrobial agent A substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans. |
| Applications: | antirheumatic drug A drug used to treat rheumatoid arthritis. immunosuppressive agent An agent that suppresses immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-cells or by inhibiting the activation of helper cells. In addition, an immunosuppressive agent is a role played by a compound which is exhibited by a capability to diminish the extent and/or voracity of an immune response. anti-anaemic agent A compound which increases either the number of red cells or the amount of haemoglobin in the blood. neuroprotective agent Any compound that can be used for the treatment of neurodegenerative disorders. antispasmodic drug A drug that suppresses spasms. These are usually caused by smooth muscle contraction, especially in tubular organs. The effect is to prevent spasms of the stomach, intestine or urinary bladder. geroprotector Any compound that supports healthy aging, slows the biological aging process, or extends lifespan. analgesic An agent capable of relieving pain without the loss of consciousness or without producing anaesthesia. In addition, analgesic is a role played by a compound which is exhibited by a capability to cause a reduction of pain symptoms. antiemetic A drug used to prevent nausea or vomiting. An antiemetic may act by a wide range of mechanisms: it might affect the medullary control centres (the vomiting centre and the chemoreceptive trigger zone) or affect the peripheral receptors. antineoplastic agent A substance that inhibits or prevents the proliferation of neoplasms. antiinfective agent A substance used in the prophylaxis or therapy of infectious diseases. anti-asthmatic agent Any compound that has anti-asthmatic effects. antiparkinson drug A drug used in the treatment of Parkinson's disease. cardiovascular drug A drug that affects the rate or intensity of cardiac contraction, blood vessel diameter or blood volume. dermatologic drug A drug used to treat or prevent skin disorders or for the routine care of skin. vulnerary A drug used in treating and healing of wounds. nephroprotective agent Any protective agent that is able to prevent damage to the kidney. renoprotective agent Any compound that is able to prevent damage to the kidneys. adrenergic agent Any agent that acts on an adrenergic receptor or affects the life cycle of an adrenergic transmitter. anti-inflammatory drug A substance that reduces or suppresses inflammation. antiatherosclerotic agent A cardiovascular drug that prevents atherosclerosis (a disease in which the inside of an artery narrows due to the build up of plaque). Compare with antiatherogenic agent. antifibrotic agent Any agent which acts to reduce fibrosis. anti-inflammatory agent Any compound that has anti-inflammatory effects. |
| ChEBI Ontology |
|---|
| Outgoing Relation(s) |
| 6α-methylprednisolone (CHEBI:6888) has role adrenergic agent (CHEBI:37962) |
| 6α-methylprednisolone (CHEBI:6888) has role analgesic (CHEBI:35480) |
| 6α-methylprednisolone (CHEBI:6888) has role anti-anaemic agent (CHEBI:75835) |
| 6α-methylprednisolone (CHEBI:6888) has role anti-asthmatic agent (CHEBI:65023) |
| 6α-methylprednisolone (CHEBI:6888) has role anti-inflammatory agent (CHEBI:67079) |
| 6α-methylprednisolone (CHEBI:6888) has role anti-inflammatory drug (CHEBI:35472) |
| 6α-methylprednisolone (CHEBI:6888) has role antiatherosclerotic agent (CHEBI:145947) |
| 6α-methylprednisolone (CHEBI:6888) has role antiemetic (CHEBI:50919) |
| 6α-methylprednisolone (CHEBI:6888) has role antifibrotic agent (CHEBI:233423) |
| 6α-methylprednisolone (CHEBI:6888) has role antifungal agent (CHEBI:35718) |
| 6α-methylprednisolone (CHEBI:6888) has role antiinfective agent (CHEBI:35441) |
| 6α-methylprednisolone (CHEBI:6888) has role antimicrobial agent (CHEBI:33281) |
| 6α-methylprednisolone (CHEBI:6888) has role antineoplastic agent (CHEBI:35610) |
| 6α-methylprednisolone (CHEBI:6888) has role antiparkinson drug (CHEBI:48407) |
| 6α-methylprednisolone (CHEBI:6888) has role antirheumatic drug (CHEBI:35842) |
| 6α-methylprednisolone (CHEBI:6888) has role antispasmodic drug (CHEBI:53784) |
| 6α-methylprednisolone (CHEBI:6888) has role antiviral agent (CHEBI:22587) |
| 6α-methylprednisolone (CHEBI:6888) has role cardiovascular drug (CHEBI:35554) |
| 6α-methylprednisolone (CHEBI:6888) has role dermatologic drug (CHEBI:50177) |
| 6α-methylprednisolone (CHEBI:6888) has role environmental contaminant (CHEBI:78298) |
| 6α-methylprednisolone (CHEBI:6888) has role geroprotector (CHEBI:176497) |
| 6α-methylprednisolone (CHEBI:6888) has role immunosuppressive agent (CHEBI:35705) |
| 6α-methylprednisolone (CHEBI:6888) has role nephroprotective agent (CHEBI:76595) |
| 6α-methylprednisolone (CHEBI:6888) has role neuroprotective agent (CHEBI:63726) |
| 6α-methylprednisolone (CHEBI:6888) has role renoprotective agent (CHEBI:231911) |
| 6α-methylprednisolone (CHEBI:6888) has role vulnerary (CHEBI:73336) |
| 6α-methylprednisolone (CHEBI:6888) has role xenobiotic (CHEBI:35703) |
| 6α-methylprednisolone (CHEBI:6888) is a 6-methylprednisolone (CHEBI:50366) |
| 6α-methylprednisolone (CHEBI:6888) is a primary α-hydroxy ketone (CHEBI:139590) |
| 6α-methylprednisolone (CHEBI:6888) is a tertiary α-hydroxy ketone (CHEBI:139592) |
| Incoming Relation(s) |
| methylprednisolone 21-suleptanic acid ester (CHEBI:156480) has functional parent 6α-methylprednisolone (CHEBI:6888) |
| methylprednisolone acetate (CHEBI:6889) has functional parent 6α-methylprednisolone (CHEBI:6888) |
| IUPAC Name |
|---|
| 11β,17,21-trihydroxy-6α-methylpregna-1,4-diene-3,20-dione |
| INNs | Source |
|---|---|
| methylprednisolone | KEGG DRUG |
| methylprednisolonum | ChemIDplus |
| metilprednisolona | ChemIDplus |
| Synonyms | Source |
|---|---|
| 1-dehydro-6α-methylhydrocortisone | ChemIDplus |
| 6-methyl-prednisolone | ChEMBL |
| 6-methylprednisolone | ChEMBL |
| (6α,11β)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione | NIST Chemistry WebBook |
| 6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione | ChemIDplus |
| J3.872E | ChEMBL |
| Brand Names | Source |
|---|---|
| Medrate | ChemIDplus |
| Medrol | KEGG DRUG |
| Medrone | DrugBank |
| Methylprednisolone component of neo-medrol | ChEMBL |
| Solomet | DrugBank |
| Urbason | DrugBank |
| Manual Xrefs | Databases |
|---|---|
| 1768 | DrugCentral |
| 1936 | VSDB |
| D00407 | KEGG DRUG |
| DB00959 | DrugBank |
| HMDB0015094 | HMDB |
| Methylprednisolone | Wikipedia |
| US2897218 | Patent |
| US3053832 | Patent |
| Citations |
|---|